Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22253312 | 1.00 | TSHR (0.43) | TSHRGAAPKMHTR2CBACE1 | |
| Hydrochloric Acid SCHEMBL29657058 | 0.99 | TSHR (0.45) | TSHRGAAPKMHTR2CBACE1 | |
| SCHEMBL22253311 | 0.81 | OPRM1 (0.44) | HTR2CALDH1A1OPRM1KMT2A | |
| SCHEMBL30803180 | 0.79 | CYP2D6 (0.49) | TSHRALDH1A1MAPK1KMT2A | |
| SCHEMBL24145829 | 0.79 | CHRM2 (0.48) | ALDH1A1OPRM1 | |
| SCHEMBL24145955 | 0.79 | TSHR (0.43) | TSHRGAAPKMHTR2CFABP7 | |
| SCHEMBL23797351 | 0.79 | TSHR (0.43) | TSHRGAAPKMHTR2CFABP7 | |
| SCHEMBL19995695 | 0.77 | ALDH1A1 (0.49) | TSHRGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL23062917 | 0.76 | TSHR (0.40) | TSHRGAAPKMHTR2CBACE1 | |
| SCHEMBL23068987 | 0.76 | TSHR (0.41) | TSHRHTR2CBACE1TACR1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326737-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | H LUNDBECK AS (DK) | 2025-10-23 | — | — | US | disclosed |
| US-12378219-B2 | Crystalline forms of a MAGL inhibitor | H. LUNDBECK A/S (DK) | 2025-08-05 | — | — | US | disclosed |
| EP-4574150-A2 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2025-06-25 | — | — | EP | disclosed |
| EP-4244208-B1 | A MAGL INHIBITOR | H LUNDBECK AS (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4519252-A1 | CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR | H. Lundbeck A/S (DK) | 2025-03-12 | — | — | EP | disclosed |
| CN-119137114-A | Crystalline forms of (S) -1- (pyridazin-3-ylcarbamoyl) -6-azaspiro [2.5] octane-6-carboxylic acid 1, 3-hexafluoropropan-2-ester as monoacylglycerol lipase inhibitors | H.隆德贝克有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-117659022-A | Ureido substituted pyridine compound, pharmaceutical composition containing ureido substituted pyridine compound and medical application of ureido substituted pyridine compound | 苏州阿尔脉生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| WO-2023213854-A1 | CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR. | H. LUNDBECK A/S (DK) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023213854-A1 | CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR. | H. LUNDBECK A/S (DK) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357190-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2023-11-09 | — | — | US | disclosed |
| US-20230357190-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2023-11-09 | — | — | US | disclosed |
| CN-116547274-A | MAGL inhibitors | H.隆德贝克有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11434222-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-09-06 | — | — | US | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434222-B2 | MAGL inhibitors | MAG, MAGI3, MAGT1 | TSHR 3957/4885GAA 438/4885PKM 4524/4885 |
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | TSHR 3957/4885GAA 438/4885PKM 4524/4885 |
| US-20250326737-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | MAG, PYM1, MAGI3 | TSHR 3432/4885GAA 1628/4885PKM 4841/4885 |
| US-12378219-B2 | Crystalline forms of a MAGL inhibitor | MAG, PYM1, MAGI3 | TSHR 3432/4885GAA 1628/4885PKM 4841/4885 |
| US-20230357190-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | MAG, PYM1, MAGI3 | TSHR 3590/4885GAA 1810/4885PKM 4848/4885 |
| US-20220153721-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | TSHR 3957/4885GAA 438/4885PKM 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.